| Project/Area Number |
16K19809
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | National Institutes for Quantum and Radiological Science and Technology (2017)
The University of Tokyo (2016) |
|---|
Principal Investigator |
Fujiwara Kentaro 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 分子イメージング診断治療研究部, 博士研究員(任常) (80766907)
|
|---|
| Research Collaborator |
HAMAKUBO Takao
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 放射免疫療法 / 小細胞肺がん / 放射線医学 / 核医学 / がん幹細胞標的治療 / Lu-177 / ROBO1 / 放射線 |
|---|
| Outline of Final Research Achievements |
Small cell lung cancer (SCLC) xenograft mice was treated by Lu-177-labeled anti-ROBO1 IgG which is an agent of radioimmunotherapy (RIT). However, no significant therapeutic effect was observed.
Sulfasarazine is a candidate therapeutic agent for cancer stem cell. We performed a combination therapy of RIT using Y-90-labeled anti-ROBO1 IgG and sulfasarazine against SCLC xenograft mice. Although there was no significant differences between the therapeutic effect of RIT only group and that of the combination group, a remarkable tumor shrinkage was observed in both groups. In the RIT only group, a complete response was observed.
|
